News

21/5/18    Article published by finfeed BARD1 Life Sciences inks critical deal to develop autoantibody test

21/5/18    Article published by StocksDigital in nextBIOTECH Top Results: BD1 Continues to Boost its Ovarian Cancer Detection Studies

18/5/18    Article published by Proactive Investors BARD1 Life Sciences signs agreement to develop custom research assay

18/5/18    Interview of BARD1 CEO Dr Leearne Hinch by Proactive Investors BARD1 Life Sciences approaching “important milestone” on path to commercialisation

9/1/18     Article published by SMALL CAPS on BARD1’s Ovarian Cancer Detection Study https://smallcaps.com.au/bard1-success-non-invasive-ovarian-cancer-detection-study/

2/1/17     Interview of BARD1 LSL Executive Director and CSO Dr Irmgard Irminger-Finger by Startwerk “BARD1AG SA: The real fight against lung cancer” https://www.startwerk.ch/2017/01/31/bard1ag-sa-the-real-fight-against-lung-cancer/

5/12/16     BARD1 Life Sciences Limited (ASX:BD1) advises that it has relocated its headquarters to the Harry Perkins Institute of Medical Research (the Perkins) at QEII Medical Centre in Nedlands, Western Australia. The Perkins houses world-class research teams, latest equipment and state-of-the-art facilities that will enable BARD1 to collaborate with Perkins’ researchers to expand its research programs in cancer diagnostics and therapeutics. BARD1’s Registered Office remains unchanged at the Subiaco address.

14/11/16     Presentation by CSO Dr Irminger-Finger at the 1st International Caparica Conference in  Splicing (12th-14th September 2016 | Caparica | Lisbon | Portugal)